stockportfolio.pro
Belite Bio, Inc (BLTE)
Healthcare · Biotechnology · NasdaqCM
Belite Bio, Inc revenue & earnings — last 4 fiscal years
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Gross profit | — | — | — | — |
| Net income | $-12.65M | $-31.63M | $-36.14M | $-77.61M |
| Net margin | — | — | — | — |
Source: Belite Bio, Inc SEC filings (10-K).
Explore 4 years of Belite Bio, Inc financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track BLTE in your portfolio →
Belite Bio, Inc financial history by metric
About Belite Bio, Inc
Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics with unmet medical needs in the United States. Its lead product candidate is Tinlarebant (LBS-008), an orally administered, which is in phase 3 clinical trial as an early intervention for maintaining the health and integrity of retinal tissues in stargardt disease type 1 and geographic atrophy patients. The company also develops LBS-009, an retinol binding protein 4 oral therapy, which is in preclinical development targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes, as well as gout. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc operates as a subsidiary of Lin Bioscience International Ltd.
Belite Bio, Inc — frequently asked questions
What is Belite Bio, Inc's revenue?
Belite Bio, Inc (BLTE) reported revenue of $0 for fiscal year 2025, according to its SEC filings.
Is Belite Bio, Inc profitable?
No — BLTE reported a net loss of $-77.61M in fiscal 2025.
What is BLTE's P/E ratio?
Belite Bio, Inc trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How much debt does Belite Bio, Inc have?
As of fiscal year 2025, BLTE carried roughly $0 in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Belite Bio, Inc's market cap?
Belite Bio, Inc (BLTE) has a market capitalization of about $5.49B, based on the latest data in our nightly-refreshed cache.
When does Belite Bio, Inc's fiscal year end?
BLTE's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
Where does this data come from?
All figures are computed from Belite Bio, Inc's official SEC filings (10-K and 10-Q), covering 4 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.